Welcome to our dedicated page for Evaxion A/S news (Ticker: EVAX), a resource for investors and traders seeking the latest updates and insights on Evaxion A/S stock.
Evaxion A/S reports developments as a clinical-stage TechBio company using its proprietary AI-Immunology™ platform to design vaccine candidates for cancer and infectious diseases. Company news commonly covers EVX-01, its personalized peptide-based cancer vaccine for advanced solid cancers, including data from a phase 2 advanced melanoma trial and measures of neoantigen target selection and immune response.
Updates also address platform applications beyond melanoma, including glioblastoma vaccine design, prophylactic infectious disease concepts such as polio and cytomegalovirus programs, collaborations, business development activity, quarterly financial results, annual general meeting outcomes, board matters, and management-role changes.
Evaxion (NASDAQ: EVAX) will release a business update and first quarter 2026 financial results on May 7, 2026, before Nasdaq opening. Management will host a conference call and webcast on the same day at 14:30 CET / 08:30 EST. Registration is required to obtain dial-in numbers and a PIN.
The webcast will open 15 minutes early and a recording will be posted on the company website shortly after the event. Contact: Mads Kronborg, Vice President, Investor Relations & Communication.
Evaxion (NASDAQ: EVAX) announced on April 27, 2026 that Birgitte Rønø, previously Chief Scientific Officer, has been promoted to a dual role as Chief Scientific Officer and Chief Operating Officer. The change follows an internal management review to align organisation structure to maximise external engagement with partners and investors. Management composition otherwise remains: Helen Tayton-Martin, CEO; Thomas Schmidt, CFO; Andreas Mattsson, Chief AI Officer. Contact: Mads Kronborg, VP Investor Relations.
Evaxion (NASDAQ: EVAX) reported phase 2 EVX-01 data showing 86% of vaccine targets triggered tumor-specific immune responses and durable two-year vaccine-specific responses.
The trial tested EVX-01 with KEYTRUDA in advanced melanoma, reported a 75% objective response rate, and will present detailed results at AACR on April 22, 2026.
Evaxion (NASDAQ: EVAX) reports new data showing its AI-Immunology™ platform can identify endogenous retrovirus (ERV)-derived antigens in glioblastoma and design vaccine candidates. Findings include bioinformatic ERV profiling, neoantigen detection in most patients, and experimental immunologic responses.
Data were generated with Duke University and will be presented at AACR on April 22, 2026 (Poster #6975).
Evaxion (NASDAQ: EVAX) held its Annual General Meeting on April 16, 2026 at its Copenhagen offices. The 2025 Annual Report was approved and the Board proposals passed. Four directors were re-elected and one new director, Jens Bitsch Nørhave, was elected. Minutes are available on the company website.
Evaxion (NASDAQ: EVAX) completed the one-year extension of its phase 2 trial of personalized cancer vaccine EVX-01, with the last patient visit on April 7, 2026.
First-two-year results showed a 75% Objective Response Rate (12/16), four complete responses, 92% still responding at two years, and high immunogenicity (81% neoantigen response). Three-year efficacy data are expected in the second half of 2026.
Evaxion (NASDAQ: EVAX) will present AI-driven polio vaccine design concepts and CMV program data at the World Vaccine Congress in Washington D.C., March 31–April 2, 2026. The company, in collaboration with the Gates Foundation, described hybrid capsid and de novo B-cell antigen approaches and will present EVX-V1 CMV antigen data on April 2, 2026.
Presentations aim to showcase AI-Immunology™ platform capabilities and early results supporting further development and potential collaborations.
Evaxion (NASDAQ: EVAX) has convened its Annual General Meeting for April 16, 2026 at 14:00 CET to be held at the company's offices in Hørsholm, Denmark. The agenda and meeting materials are available on the company's investor website, and investor contact details are provided for further questions.
Evaxion (NASDAQ: EVAX) announced two abstracts accepted for presentation at the AACR Annual Meeting in San Diego, April 17-22, 2026. One poster reports new biomarker and immunogenicity data for the personalized cancer vaccine EVX-01 in advanced melanoma; the other reports use of the AI-Immunology™ platform to identify ERV-derived neoantigens for personalized glioblastoma vaccines. Evaxion will also attend the AACR Oncology Industry Partnering event to seek partnerships and collaborations. Presentations are scheduled on April 22, 2026, at 9:00–12:00 CST (16:00–19:00 CET).
Evaxion (NASDAQ: EVAX) reported full-year 2025 results and a business update on March 5, 2026, highlighting a transformational year driven by partnerships, clinical data and stronger finances. Key items: licensing of EVX-B3 to MSD, EVX-01 phase 2 two-year data (75% ORR; 92% durable responders at two years), new candidates EVX-04 and EVX-B4, $7.5M option fee plus up to $592M milestones, cash of $23.2M funding operations into H2 2027, and net loss of $7.7M for 2025.
The company expects ~ $14M operational cash burn in 2026 and plans autoimmune expansion of its AI-Immunology™ platform.